Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Merger or Acquisition (July 2025)
11 slides from Natco Pharma's merger presentation, Jul 23, 2025
Slide 1: Filing cover letter to stock exchanges
23rd July 2025 Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: - Investor Presentation Please find enclosed herewith the Investor Presentation on P
Slide 2: NATCO Pharma Limited – Investment Presentation – Proposed Investment
NATCO Pharma Limited Investment Presentation – Proposed Investment
Slide 3: Transaction Summary
Transaction Summary NATCO Pharma Limited The Bidvest 35.75% Group SOUTH AFRICA Limited 64.25% Target Geography Proposed Shareholding ZAR 75 ZAR 4 Bn US$ 226 Mn1 ~US$ 10 Mn US$ 4.271 ₹ 2,000 Cr Price per share Cost to NATCO Transaction Cost 484 507 536 262 7.83 1.12 FY22 FY23 FY24 H1FY25 Revenue in U
Slide 4: Adcock Ingram - Profile
Adcock Ingram - Profile Established in 1890 as a pharmacy in Krugersdorp, South Africa and evolved to be one of the biggest pharmaceutical and healthcare companies on the African continent Second-largest South African based pharmaceutical company in terms of private market share Engages in the manuf
Slide 5: Adcock Ingram - Four Commercial Divisions
Adcock Ingram - Four Commercial Divisions PRESCRIPTION OVER THE COUNTER HOSPITAL CONSUMER (OTC) • Focuses on offering a • Focuses on the • Manufacturers and • Focuses on marketing, broad range of manufacturing, marketing supplies hospital and selling and distribution of medicines in targeted and sel
Slide 6: Adcock Ingram - Top Ten Products
Adcock Ingram - Top Ten Products Panado Epi-max Allergex Adco-dol Bioplus Consumer Consumer OTC OTC Consumer Analgesic Emollient Anti-Allergic Pain relief Multi-Vit Energy Booster Corenza C Citro-Soda IV Solutions Viaflex Dianeal Solution Synaleve OTC OTC Hospital Hospital Prescription Cold & Flu An
Slide 7: Adcock Ingram - Financial Performance
Adcock Ingram - Financial Performance INCOME STATEMENT (Financial year July – June) US$ Mn FY22 FY23 FY24 H1- FY25 (Dec’24) Revenue 484 507 536 262 EBITDA 74 81 78 38 EBITDA% 15% 16% 15% 14% Net profit 44 50 45 22 Net profit% 9% 10% 8% 8% NATCO will consolidate 35.75% of Net Profit of Adcock Ingram
Slide 8: Adcock Ingram - Transaction Rationale
Adcock Ingram - Transaction Rationale + Multiple value creation opportunities from a combination with NATCO ✓ NATCO has a strategic focus on global presence including EMs and has already established front-ends in USA, Canada, Brazil, Philippines, Singapore, Australia, Indonesia and actively operatin
Slide 9: Adcock Ingram - Potential Synergies
Adcock Ingram - Potential Synergies Broad Contours Type ✓Marketing & distribution of NATCO's products (current and future) in SA through Adcock Revenue synergy ✓Introduction of affordable and innovative pharmaceutical products in African markets – create a Revenue synergy/ market leading pharmaceuti
Slide 10: Corporate Profile – Bidvest Group Limited – The other shareholder
Corporate Profile – Bidvest Group Limited – The other shareholder Founded in 1988 and listed on the JSE, the Bidvest Group Limited is a leading business-to- business services, trading, and distribution Group with a blended portfolio of defensive and cyclical businesses that are diversified, essentia
Slide 11: Thank You
THANK YOU https://twitter.com/pharma_natco Contact Information https://www.linkedin.com/company/natcopharma ir@natcopharma.co.in Website: www.natcopharma.com